Company
Triumvira
Empowering the body’s natural defenses against life-threatening cancers.
Also known as Triumvira Immunologics, Triumvira Immunologics Inc.
- Status
- Operatingas of 2026-09-20
- Business model
- B2B
- Legal name
- Triumvira Immunologics Inc.
- triumvira.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Triumvira is developing unique, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat a broad range of patients with cancer.
Funding snapshot
- Total raised
- $59.7MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $59.7M2021-04-26
Funding rounds
- Round, 2021
- $59.7M2021-04-26, SEC form D sold, 13 investors
Loading relationship preview